N-ethyl-N-nitrosourethane

07/01/1989 - "In groups given 0.6 ppm or more ENUR, digestive tract tumors were induced dose-dependently. "
07/01/1989 - "Significant increase of the total tumor incidences and shortening of the mean survival times were observed in groups given 2.5 and 10 ppm ENUR. "
02/01/1982 - "Tumors of the forestomach were more frequent than those of the esophagus and oral cavity and/or pharynx in groups treated with ENUR. "
10/01/1979 - "In addition, topical application of ENUR induced tumors of the skin as well as tumors of the forestomach and liver."
02/01/1982 - "In the groups treated with ENUR, tumors were most frequent in the upper digestive tract and duodenum, whereas in groups given ANUR tumors were induced only in the upper digestive tract, with none in the duodenum. "

05/01/1998 - "In the forestomach, the incidences of papillomas and carcinomas were also significantly elevated only in the group treated with ENUR followed by 0.125% HTHQ. "
05/01/1998 - "Tongue papillary hyperplasia and papillomas tended to be increased in the groups treated with ENUR followed by 0.5-0.125% HTHQ, though there was no effect at the highest dose, in line with increased bromodeoxyuridine labeling indices. "

05/01/1998 - "Without ENUR pretreatment, papillary hyperplasia was found in the 1-0.125% HTHQ groups and the labeling index was also increased, though without clear dose dependence. "
05/01/1998 - "Tongue papillary hyperplasia and papillomas tended to be increased in the groups treated with ENUR followed by 0.5-0.125% HTHQ, though there was no effect at the highest dose, in line with increased bromodeoxyuridine labeling indices. "

05/01/1998 - "In the forestomach, the incidences of papillomas and carcinomas were also significantly elevated only in the group treated with ENUR followed by 0.125% HTHQ. "